Eric Blanchard

Cooley advised Uber Technologies, a technology platform that uses a massive network, top technology, operational excellence and product expertise to power movement from Point A to Point B, on its $4 billion investment-grade bond offering.

Cooley advised Perceptive Advisors, a top healthcare investment firm, and its affiliates, including Perceptive Discovery Fund, on its definitive merger agreement with Vapotherm, a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, and listed as VAPO on the over-the-counter quotation exchange (OTCQX).

Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics, a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Cooley advised Beam Therapeutics, a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines, on its agreement with Verve Therapeutics to sell its opt-in rights to co-develop and co-commercialize base-editing programs for cardiovascular disease to Eli Lilly and Company.